Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $7.3 million.

  • Viking Therapeutics' Share-based Compensation fell 1832.55% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.9 million, marking a year-over-year increase of 3474.84%. This contributed to the annual value of $29.7 million for FY2024, which is 7738.51% up from last year.
  • Latest data reveals that Viking Therapeutics reported Share-based Compensation of $7.3 million as of Q3 2025, which was down 1832.55% from $13.5 million recorded in Q2 2025.
  • Viking Therapeutics' Share-based Compensation's 5-year high stood at $13.5 million during Q2 2025, with a 5-year trough of $1.4 million in Q4 2021.
  • Its 5-year average for Share-based Compensation is $4.9 million, with a median of $4.1 million in 2023.
  • In the last 5 years, Viking Therapeutics' Share-based Compensation surged by 13097.94% in 2023 and then tumbled by 1832.55% in 2025.
  • Viking Therapeutics' Share-based Compensation (Quarter) stood at $1.4 million in 2021, then soared by 50.45% to $2.2 million in 2022, then skyrocketed by 89.24% to $4.1 million in 2023, then surged by 38.9% to $5.7 million in 2024, then rose by 29.45% to $7.3 million in 2025.
  • Its Share-based Compensation stands at $7.3 million for Q3 2025, versus $13.5 million for Q2 2025 and $11.3 million for Q1 2025.